Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Teplizumab Curtailed Herold

Monoclonal antibody · developed by MacroGenics

Phase 3 Most advanced trial (none active)
MGNX Developer
1 Registered trials

What is Teplizumab Curtailed Herold?

Teplizumab Curtailed Herold is a dosing regimen of teplizumab given intravenously, with full-dose treatment for 6 days followed by 8 days of placebo, repeated at Week 26. It is studied in type 1 diabetes mellitus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Therapy area
Endocrine
Developer
MacroGenics (MGNX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00920582 Phase 3 Type 1 Diabetes Mellitus Terminated MGNX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Type 1 Diabetes Mellitus

More from MacroGenics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.

Follow MGNX, the company behind Teplizumab Curtailed Herold

See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGNX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.